Business
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.Dr. Pruthi is an accomplished physician-scientist and executive with more than 20...
About this update from Preveceutical Medical Inc
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.","length":435,"tagName":"p"},{"type":"text","content":"Dr. Pruthi is an accomplished physician-scientist and executive with more than 20 years of experience spanning academic medicine, global pharmaceutical leadership, and biotechnology innovation. In his new role, he will contribute to shaping the Company's clinical development strategy and advancing key initiatives, including its Sol-gel program, Nature Identical™ peptide platform, non-addictive pain management therapies, and dopamine-based treatments targeting Parkinson's disease.","length":492,"tagName":"p"},{"type":"text","content":"Bringing extensive experience in clinical trial design, regulatory strategy, and organizational leadership, Dr. Pruthi has worked closely with global regulatory agencies such as the FDA and EMA and has been actively involved in capital markets initiatives. He currently serves as Chief Medical Officer of Relmada Therapeutics, Inc., a position he has held since June 2025. There, he leads development of the NDV-011 bladder cancer program, including a Phase 2 study and preparations for a global Phase 3 registrational trial expected to commence in early 2026. His responsibilities have included stakeholder engagement, trial execution, and collaboration with investors and regulatory authorities. He also played a central role in financing efforts that generated over $100 million through a public offering and an additional $160 million via a PIPE transaction.","length":862,"tagName":"p"},{"type":"text","content":"From 2022 to 2024, he held senior leadership roles in oncology at Johnson & Johnson Innovative Medicine (Janssen), where he contributed to late-stage clinical development, including multiple Phase 3 trials and regulatory submissions. His work supported approvals from both the FDA and EMA, including the approval of TAR-200 in 2025 for certain bladder cancer patients. He also incorporated patient-reported ou...